Merck’s Bezlotoxumab C. Difficile Data Pave Way For Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Company readies regulatory filings for bezlotoxumab as a monotherapy in preventing C. difficile, following presentation of positive MODIFY I and II data at the ICAAC meeting in San Diego.
You may also be interested in...
Merck Went Own Way On Bezlotoxumab Endpoint And FDA May Not Follow
Merck rejected FDA's recommended endpoint to show efficacy in preventing C. difficile recurrence, which could make it difficult to gain approval for the product, headed to June 9 advisory panel review.
Keeping Track: Telework Kept FDA On Track During Blizzard
The latest drug development news and highlights from our FDA Performance Tracker.
Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky
Anti-infective start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it. Profiles of EnBiotix, Nosopharm, and Spero Therapeutics.